Larimar Therapeutics, Inc. beat EPS estimates 50% of the time across 2 reported quarters (1 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.39 | — | — | Miss |
| Q12026 FY2026 | $-0.53 | $-0.31 | +41.5% | Beat |
| Q42025 FY2025 | $-0.44 | $-0.73 | -65.9% | Miss |
Back to LRMR overview · LRMR holders · LRMR KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.